Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
LARGO, Fla., April 21, 2010 (GLOBE NEWSWIRE) -- GeoPharma, Inc. (Nasdaq:GORX) (the "Company") announced today that since December 31, 2009, it has reduced its 12% convertible debt (the "Debt...
LARGO, Fla., March 2, 2010 (GLOBE NEWSWIRE) -- GeoPharma, Inc. (Nasdaq:GORX) (the "Company") announced today that the FDA Office of Compliance has completed the evaluation of its Largo, Florida...
LARGO, Fla., March 1, 2010 (GLOBE NEWSWIRE) -- GeoPharma, Inc. (Nasdaq:GORX) (the "Company") is hosting a conference call on March 2, 2010 at 11 a.m. ET to discuss the Fiscal Year 2010 Third...
LARGO, Fla., Feb. 23, 2010 (GLOBE NEWSWIRE) -- GeoPharma, Inc. (Nasdaq:GORX) (the "Company") announced today the results of its fiscal year 2010 third quarter which ended December 31, 2009, with...
GeoPharma, Inc. (NASDAQ:GORX) (the ?Company?) announced its Fiscal Year 2009 second quarter results for the period ended September 30, 2008, reporting revenues of $16,039,751...
GeoPharma, Inc. (NASDAQ:GORX) (the ?Company?) announced its Fiscal Year 2009 First Quarter Results reporting revenues of $20,025,307 representing a 105% increase over the...
Contact phone number should read: Alexander Nachman, 727-471-0850, ext. 243 (sted Alexander Nachman, 727-471-0871, ext. 243). The corrected release reads: WEBCAST ALERT:...
GeoPharma Inc. (Nasdaq: GORX) announces the following Webcast: What: ? Fiscal Year 2009 First Quarter Earnings Release and Conference Call...
LARGO, Fla., July 21 /PRNewswire-FirstCall/ -- GeoPharma, Inc. (NASDAQ:GORX) (the "Company") announced today the expansion of the distribution agreement between the Company and Cura...
GeoPharma, Inc. (NASDAQ:GORX) (the ?Company?) announced today a second consecutive quarter of record revenues reporting an unprecedented $23,890,000 for the fiscal fourth...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
